Biocracked
Approach: conceptual metaphor. Palette: bold color field.

Subject: a heavy steel hand-brake lever from a bicycle or machine, shown in tight close-up, half-released with its cable going slack. A taut, braided rope of dense red muscle-like fibers runs through the frame, pulling free of the brake. The surface is lightly scuffed and brushed, with a thin electric green (#00e676) cable sleeve as the one small accent.

Camera: low three-quarter angle, 85mm lens, shallow depth of field, the lever sharp in the foreground and the rope softening behind it.

Lighting: crisp, directional studio light from the upper left, with hard-edged but clean shadows and warm highlights on the metal.

Backdrop: a seamless, saturated mustard-yellow field, evenly lit and uncluttered, with no blue cast anywhere.

Mood: tense but hopeful, a mechanism being released, with a hint of caution in the sharp shadows.
Longevity

Dakile Myostatin Yana Rage Ragin Tsokoki Na Semaglutide, Amma Da Wani Ƙalubale

Dr. Synapse · · 5 min read

Semaglutide na iya narkar da mai, kuma na iya rage ƙarfin tsoka. Wani babban gwaji na mataki na 2 da aka wallafa a The Lancet ya binciki ko dakile “birkin” jiki kan girman tsoka zai iya hana wannan ragin. Amsa ita ce eh, amma da wasu sharuɗɗa, kuma wani salo na maganin ya nuna alamun rashin lafiya da ya kamata a kula da su.

Ga abin da gwajin COURAGE ya gano, abin da ba ya gano, da abin da masu amfani da GLP‑1 za su iya yi a yau.

Matsalar: Ragin Kiba Ba Fat Ba Kawai

Ragin kiba da magungunan GLP‑1 receptor agonists ke haifarwa yana zuwa da raguwar tsoka sosai. A cikin COURAGE, waɗanda suka karɓi semaglutide da placebo sun rasa 6.6 % na lean mass a makonni 26 (95 % CI −7.4 zuwa −5.7). A ɓangaren makonni 52, ƙungiyar placebo ta rasa 7.3 % na lean mass.

Lean mass ba daidai yake da tsokar ƙashi ba, amma shi ne ma’aunin farko da aka yi amfani da shi a gwajin kuma ana ɗaukarsa wakilin yanayin ƙoshin lafiya.

Shawara: Dakile Myostatin (GDF8) da Activin A

GDF8, wanda aka fi sani da myostatin, da activin A suna aiki ta hanyar masu karɓar ActRIIA/B a matsayin masu hana ci gaban tsoka. Regeneron ta haɓaka nau’ikan antibodies guda biyu:

  • Trevogrumab, wanda ke dakile GDF8; ana ba da shi a kowane mako ta allurar subcutaneous.
  • Garetosmab, wanda ke dakile activin A; ana ba da shi a cikin infusion na jini duk bayan makonni 4.

Gwaji: Mutane 975, Bangarori Biyu

Binciken ya kasance double‑blind, placebo‑controlled, mataki na 2 a cibiyoyi 60 a Amurka. An haɗa mutane 975 masu kiba (BMI ≥ 30), shekaru matsakaicin 49, da BMI matsakaicin 36.7. Kashi sittin da huɗu cikin ɗari (64 %) mata ne. Kowa ya sha semaglutide, an daidaita zuwa 2.4 mg a kowane mako.

  • Bangare A (makonni 26, n=605): placebo, trevogrumab 200 mg, trevogrumab 400 mg, ko trevogrumab 400 mg da garetosmab 10 mg/kg.
  • Bangare B (makonni 52, n=376): placebo, trevogrumab 25 mg, ko trevogrumab 75 mg.

Lambobin Manyan Sakamako: Lean Mass

Kididdigar da ke ƙasa suna nuna bambancin magani da aka kiyasta idan aka kwatanta da semaglutide da placebo.

Bangare A (makonni 26):

  • Trevogrumab 200 mg: +3.1 % (95 % CI 1.9 zuwa 4.3)
  • Trevogrumab 400 mg: +2.7 % (1.5 zuwa 4.0)
  • Trevogrumab 400 mg da garetosmab: +4.5 % (3.1 zuwa 5.9)

Bangare B (makonni 52):

  • Trevogrumab 25 mg: +1.5 % (‑0.3 zuwa 3.3), ba a samu muhimmanci na ƙididdiga ba
  • Trevogrumab 75 mg: +3.1 % (1.3 zuwa 4.9)

Magungunan sun rage raguwar lean mass amma ba su kawar da ita gaba ɗaya ba. Takaitaccen bayanin ba ya ba da cikakken canjin lean mass na rukuni‑rukuni, don haka duk wani “ragi na ƙarshe” da muka ƙirga, yana kanmu ne.

Rage Mai Da Kiba: Abin Mamaki

Ana ɗaukar magungunan da ke tsare tsoka a matsayin na da ƙyamar rage mai. A wannan binciken, a wasu rukuni, aka samu akasin haka.

  • Rukuni na placebo ya rasa 15.6 % na maɗan mai a Bangare A.
  • Trevogrumab 400 mg kadai ya haifar da raguwar mai mai girma (ETD ‑3.4 %).
  • Haɗin trevogrumab da garetosmab ya ƙara raguwar mai sosai (ETD ‑11.7 %).
  • Nauyin jiki ya sauka 10.6 % a kan semaglutide da placebo; haɗin ya ƙara inganta wannan da ƙarin 2.7 %.
  • Babu wani rukuni a Bangare A ko B da ya nuna bambanci mai mahimmanci a kan maɗan mai ko nauyin jiki.

Kalubalen: Tsarin Tsaron Haɗin

Trevogrumab kadai, a kowane ƙima (25, 75, 200 ko 400 mg), an samu karɓuwa mai kyau, tare da tsarin tsaro da ya yi kama da semaglutide da placebo. Matsalolin hanji sune mafi yawan faruwa kuma sun zo a kusan adadi iri ɗaya a dukkan rukuni. Mafi yawan mummunan abubuwa sun kasance masu sauƙi zuwa matsakaici.

Rukuni na trevogrumab 400 mg da garetosmab ya bambanta:

  • Mummunan abubuwa masu tsanani: 14 daga 149 (9 %)
  • Dakatar da magani: 48 daga 149 (32 %)
  • Ciwon tsoka (muscle spasms): 61 daga 149 (41 %), idan aka kwatanta da 8 % (23 daga 299) a rukuni na trevogrumab kadai da 5 % (7 daga 151) a placebo
  • Mutuwar mutane: biyu a lokacin gwajin, duka a wannan rukuni. Masu binciken ba su gano alaƙa kai tsaye ba.

Mawallafa sun ƙare da cewa haɗin ba shi da “favourable safety and tolerability.” Sun gabatar da trevogrumab kadai a matsayin hujja mafi inganci.

Gargadi

  • Tallafin kuɗi: Regeneron ta ɗauki nauyin gwajin, kuma yawancin marubuta ma’aikatan Regeneron ne da masu hannun jari.
  • Mataki na 2: Manyan manufofi su ne yanayin jiki da nauyi, ba aikin jiki ba. Mawallafa suna cewa akwai buƙatar ƙarin bincike don tantance ko kiyaye lean mass zai haifar da ingantaccen aiki da lafiya ta metabolic.
  • Ba a amince da su ba: Babu ɗayan antibodies da aka amince da su don wannan amfani. Ba za a iya samun su a matsayin kari ko takardar magani ba.
  • Lokacin janye magani: Bangare A ya ƙunshi makonni 26 bayan an daina semaglutide, amma takaitaccen ba ya bayar da sakamako daga wannan ɓangaren.

Abin Da Wannan Ke Nufi Ga Masu Amfani Da GLP‑1 Yanzu

Wannan jagora ne na gabaɗaya, ba sakamakon binciken da ya gwada motsa jiki ko abinci ba.

  • Kada ku bi wannan nau’in magani. Babu ƙuduri, lokaci ko “wanda ya dace da shi” domin babu wani abu da ake samu a wajen gwaje‑gwaje.
  • Mayar da hankali kan furotin da horon ƙarfi. Waɗannan su ne hanyoyin da aka fi ba da shawara, masu sauƙi, don kare tsoka yayin ragin kiba. Ku tattauna adadin furotin da shirin motsa jiki da likita ko ƙwararren mai ba da abinci, musamman idan kuna da cutar koda.
  • Ku bi diddigin fiye da sikeli. Ƙarfi, aiki da, inda zai yiwu, yanayin jiki na ba ku ƙarin bayani fiye da nauyi kai‑kai.

Jadawalin Lokaci

Takaitaccen bai ba da lokacin amincewa ba. COURAGE yana ci gaba amma ba a karɓar sababbin mahalarta ba. Saboda tsarin tsaron haɗin ya kasance mai damuwa kuma ba a tantance aikin jiki ba, za a buƙaci ƙarin gwaje‑gwaje kafin kowanne hukuma ta yi la’akari da waɗannan magungunan. Ku ɗauki wannan a matsayin alamar farko mai ɗaukar hankali, ba zaɓi da ke tafe nan ba.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach: conceptual metaphor. Palette: bold color field.

A single ripe, glossy red tomato-colored apple sits at the center of a saturated mustard-yellow seamless backdrop, with a neat row of five identical white capsules lined up beside it on the same surface. The apple is the clear winner of the frame. One capsule has rolled slightly away, cracked open and spilling a tiny pile of pale powder. Shot at a low three-quarter angle with a shallow depth of field, so the back capsules blur softly. Lighting is a large, soft key light from the upper left, giving crisp but gentle shadows with warm yellow bounce. A thin sprig of electric green (#00e676) leaves rises from the apple stem as the only green accent. Mood: confident, playful and skeptical, a clean verdict that real food outweighs pills. No text or labels.
longevity

Karin Gaba a kan Kwayoyin “Zombie”? Binciken Mutane 27 Ya Nuna Cin Abinci Ya Fi Magunguna Tasiri

BY NOVA CHEN ·

Lakabin ƙarin abinci na ɗauke da alƙawarin “share kwayoyin zombie”, amma sabon binciken da ya haɗa gwaje‑gwajen mutane 27 da mahalarta 3,811 ya nuna shaidar ba ta da ƙarfi. Rage ƙalori ne ya haifar da raguwar alamun kumburi da ke alaƙa da tsufa. Omega‑3 ita ce ƙarin da ya fi fatan, duk da cewa shaidar ta iyakance kuma ta bambanta. Tsawon telomere da alamu na p16/p21 ba su nuna wani sauyi ba. Ga abin da hakan ke nufi game da abincin da kuke ci da abin da kuke siya.

Approach: Macro science. Palette: D, bold color field.

An extreme close-up microscopy-style photograph of a single giant megakaryocyte cell, a large lumpy, lobed cell with a textured, slightly translucent surface, budding off dozens of tiny, smooth, disc-shaped platelets that drift away on fine stringy extensions. The cell and platelets are a warm pearly ivory with subtle coral-pink internal granules and a few small electric green (#00e676) fluorescent specks inside, suggesting recycling vesicles. The backdrop is a saturated, even tomato-red to deep orange color field with a soft gradient. Shot from slightly above at a three-quarter angle, with shallow depth of field so the nearest platelets are crisp and the distant ones melt into soft blur. Lighting is clean, diffuse and glowing from behind, giving gentle rim highlights. Mood: curious, precise, quietly cautionary. No text.
longevity

CoQ10 Ya Kwantar da ‘Tsoffin’ Platelet a Berayen Tsufa — Abin da Ya Kamata a Lura

BY NOVA CHEN ·

Sabuwar bincike a mujallar *Aging Cell* ya nuna CoQ10 na inganta aikin megakaryocytes masu tsufa a beraye, wanda ke rage haɗa‑haɗar platelet da ƙara kwanciyar su. Tasirin ya danganta da COPS3 da autophagy, amma binciken ya ƙunshi kawai beraye da ƙwayoyin a dakin gwaje‑gwaje; ba a sami bayanan mutane ba, kuma ba a tabbatar da cewa zai hana toshewar jini ba. Ga abin da ke nufi, abin da ba ya nufi, da kuma dalilin da ya sa masu amfani da magungunan rage jini su tattauna da likita kafin ɗaukar CoQ10.

Approach 2, lab in action, with palette D, bold color field.

Overhead-angled close shot of a gloved hand in a pale purple nitrile glove holding an open agar petri dish above a saturated mustard-yellow lab bench. Inside the dish, dozens of tiny translucent C. elegans worms trace sinuous curved tracks across a faintly glowing bacterial lawn. A small cluster of the worms shows a subtle electric green fluorescence along their bodies, suggesting neurons. Beside the dish, a microcentrifuge tube holds a pale golden-yellow DHM solution, with a pipette tip hovering nearby. Lighting is bright, crisp, directional studio-style lab light with soft short shadows. The shallow depth of field blurs the background to a smooth yellow. The mood is curious, precise and optimistic, with a slightly playful contrast between the vivid backdrop and the delicate, nearly invisible animals.
longevity

Karin Kayan Hangover DHM Ya Kara Tsawon Rayuwar Tsutsa Har Zuwa Kashi 15%

BY NOVA CHEN ·

Wannan sinadarin DHM da ake samu a cikin ƙwayoyin “hangover” ya tsawaita rayuwar tsutsa da kashi 15 % a gwajin *Caenorhabditis elegans*. Bugu da ƙari, yana kare ƙwayoyin jijiyoyi, yana riƙe motsin su na tsawon lokaci, kuma yana rage kitse a hanji. Tasirin ba ya dogara da sanannen gen ɗin *daf‑16*, kuma ba a ga ƙaruwa a masu nuna antioxidant ba, alamar wata hanya dabam. Sai dai gwajin ya ƙunshi tsutsa ne kawai; ba a samu bayanai kan tasiri a mutane ba.

**Approach: Macro science. Palette: Bold color field (saturated magenta).**

Extreme macro photograph of fisetin-like yellow needle crystals growing from a single point, with two larger, more geometric, translucent amber-gold crystals standing slightly apart as the "upgraded" versions. The crystals show real facets, internal fractures and sharp refractive edges. They rest on a glossy, saturated magenta surface that fills the background in a smooth gradient and reflects a faint mirror image of the crystals. Shot from a low three-quarter angle with a shallow depth of field, so the foreground crystal tips are razor sharp and the rest melts into soft magenta bokeh. Lighting is a crisp, warm-white key from the upper left, with strong specular highlights and a thin rim of electric green (#00e676) light catching one crystal edge. Mood: precise, curious, and slightly skeptical, like a lab specimen under scrutiny.
longevity

Fisetin Ba Shi da Ƙarfi? Masana Sun Kirkiro Nau'ikan Ingantattu Biyu

BY DR. SYNAPSE ·

Masana da ke bayan sabon takardar *Aging Cell* sun bayyana cewa fisetin, wani sinadirin senolytic da ke cikin gwaje‑gwajen kliniki, ba shi da tasiri yadda ake bukata kuma ba a sha shi da yawa. Saboda haka suka ƙirƙiri nau'ikan ingantattu guda biyu – SR29384 da SR31133 – waɗanda suka rage tsufar ƙwayoyin a cikin ƙashi da suka inganta al'amuran lafiya a cikin berayen da ake amfani da su a matsayin misalin tsufa. Amma babu bayanan da suka shafi mutane, ba za a iya sayen waɗannan sinadarai ba, kuma marubutan sun bayyana kamfanin da haƙƙin ƙirƙira da suka danganta da su. Ga abin da hakan ke nufi idan ka ci fisetin a yau, da waɗanda ya kamata su yi taka tsantsan.

This page is available in